B. Trottier

发表

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

R. Hogg, J. Montaner, M. Wainberg, 2017, BMC Infectious Diseases.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

J. Montaner, D. Kuritzkes, S. Walmsley, 2003, The New England journal of medicine.

HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness

C. Tremblay, D. Rouleau, J. Routy, 2017, PloS one.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Effectiveness of Step-Wise Intervention Plan for Managing Nelfinavir-Associated Diarrhea: A Pilot Study

J. Macleod, S. Walmsley, A. Rachlis, 2005, HIV clinical trials.

Increased carotid artery wall stiffness and plaque prevalence in HIV infected patients measured with ultrasound elastography

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2020, European Radiology.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Prevalence and Characterization of Subclinical Coronary Atherosclerotic Plaque with CT among Individuals with HIV: Results from the Canadian HIV and Aging Cohort Study.

J. Leipsic, C. Tremblay, C. Chartrand-Lefebvre, 2021, Radiology.

Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.

S. Trottier, C. Tremblay, D. Rouleau, 2007, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy

V. Nguyen, Réjean Thomas, N. Machouf, 2012, HIV clinical trials.

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration *

J. Montaner, C. Kovacs, D. Rouleau, 2007, HIV medicine.

A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

B. Gazzard, C. Leen, B. Yip, 2017, HIV medicine.

Socio‐economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015

C. Tremblay, J. Routy, Réjean Thomas, 2018, Journal of the International AIDS Society.

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation

J. Routy, J. Albu, S. Grinspoon, 2005, AIDS.

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

J. Singer, V. Martel-Laferrière, C. Tremblay, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of NKG2C Genotypes on HIV Susceptibility and Viral Load Set Point

C. Tremblay, D. Rouleau, J. Routy, 2021, Journal of virology.

Growth differentiation factor-15 as a biomarker of atherosclerotic coronary plaque: Value in people living with and without HIV

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2022, Frontiers in Cardiovascular Medicine.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

M. Wainberg, C. Tremblay, L. Vézina, 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs.

S. Trottier, C. Tremblay, C. Chartrand-Lefebvre, 2019, Journal of acquired immune deficiency syndromes.

Effects of drug resistance on viral load in patients failing antiretroviral therapy

M. Wainberg, J. Routy, Viet-An Nguyen, 2006, Journal of medical virology.

Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2

G. di Perri, M. Peeters, J. Vingerhoets, 2010, HIV clinical trials.

Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2022, bioRxiv.

Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study

S. Trottier, T. Hart, R. Hogg, 2017, BMC Research Notes.

High frequencies of adaptive NK cells are associated with absence of coronary plaque in cytomegalovirus infected people living with HIV

C. Tremblay, C. Chartrand-Lefebvre, J. Baril, 2022, Medicine.

Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients

C. Katlama, M. Johnson, M. Peeters, 2008 .

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

B. Clotet, C. Katlama, M. Johnson, 2007, The Lancet.

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

J. Lake, M. Aboud, B. Wynne, 2017, Antiviral therapy.

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

C. Tremblay, J. Villeneuve, R. Lalonde, 2011, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2019, Front. Immunol..

CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2019, Front. Immunol..

Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak

M. Graham, D. Vinh, Réjean Thomas, 2022, Annals of Internal Medicine.

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2017, BMC Infectious Diseases.

A Latent Class Analysis of the Social Determinants of Health Impacting Heavy Alcohol Consumption Among Women Living with HIV in Canada: The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study

S. Trottier, T. Hart, A. Burchell, 2019, AIDS and Behavior.

Argon plasma coagulation treatment of anal high‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study

D. Rouleau, J. Macleod, F. Coutlée, 2018, HIV medicine.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee.

D. Rouleau, J. Routy, N. Lapointe, 2011, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

C. Farthing, D. Cooper, S. Walmsley, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Bernard Hirschel, Adriano Lazzarin, B. Hirschel, 2008, The New England journal of medicine.

Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers

C. Tremblay, D. Rouleau, J. Routy, 2020, Frontiers in Immunology.

Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-Naïve HIV-lnfected Patients

C. Tremblay, M. Loutfy, A. Rachlis, 2011, HIV clinical trials.

Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort

Réjean Thomas, D. Murphy, N. Machouf, 2015, PloS one.

Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis

S. Gange, C. Tremblay, C. Chartrand-Lefebvre, 2021, Frontiers in Immunology.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

C. Tremblay, B. Brenner, D. Rouleau, 2018, Retrovirology.

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors

S. Trottier, J. Singer, C. Kovacs, 2016, Scientific Reports.

Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection

C. Tremblay, A. Chamberland, D. Rouleau, 2011, International journal of STD & AIDS.

Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection

C. Tremblay, D. Rouleau, J. Routy, 2021, Journal of virology.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

R. Haubrich, B. Clotet, C. Katlama, 2010, Antiviral therapy.

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results

J. Baeten, H. Dvory‐Sobol, J. Molina, 2022, Open Forum Infectious Diseases.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

P. Harrigan, B. Yip, R. Hogg, 2016, BMC Infectious Diseases.

The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol

S. Trottier, M. Abrahamowicz, C. Kovacs, 2017, BMC Infectious Diseases.

Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals

C. Tremblay, D. Rouleau, J. Routy, 2019, Viruses.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir

S. Trottier, J. Singer, C. Tremblay, 2012, HIV clinical trials.

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV‐1 reservoirs: results from a multicentre randomized clinical study

S. Trottier, J. Singer, C. Tremblay, 2012, HIV medicine.

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

M. Gill, A. Rachlis, J. Angel, 2010, Tissue antigens.

Sexual Anxiety Among Women Living with HIV in the Era of Antiretroviral Treatment Suppressing HIV Transmission

S. Trottier, T. Hart, A. Burchell, 2020, Sexuality Research and Social Policy.

Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study

S. Trottier, T. Hart, R. Hogg, 2017, BMC Research Notes.

P-01-066 PrEP in Montreal: good adherence, no seroconversion and no evidence of risk compensation

Réjean Thomas, N. Machouf, B. Trottier, 2016 .

A Model of Quality of Life of Women Living With HIV

M. Zunzunegui, D. Rouleau, G. Godin, 2012 .

Establishing the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study

S. Trottier, T. Hart, R. Hogg, 2016, BMC Medical Research Methodology.

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

M. Wainberg, C. Delaugerre, C. Tremblay, 2018, Open forum infectious diseases.

Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen

S. Trottier, C. Kovacs, J. Sampalis, 2007, HIV clinical trials.

Covid-19 vaccine immunogenicity in people living with HIV-1

V. Martel-Laferrière, D. Kaufmann, C. Tremblay, 2021, bioRxiv.

Epicardial fat density, coronary artery disease and inflammation in people living with HIV

C. Chartrand-Lefebvre, J. Baril, Madeleine Durand, 2023, Medicine.

The Frequency and Function of NKG2C+CD57+ Adaptive NK Cells in Cytomagalovirus Co-Infected People Living with HIV Decline with Duration of Antiretroviral Therapy

C. Tremblay, J. Routy, J. Bruneau, 2023, Viruses.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

C. Cohen, S. Esser, Don E. Smith, 2016, AIDS care.

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

D. Ward, P. Sax, Y. Yazdanpanah, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

J. Routy, D. Margolis, D. Asmuth, 2016, Journal of acquired immune deficiency syndromes.

A Prospective Randomized Controlled Trial of Structured Treatment Interruption in HIV-Infected Patients Failing Highly Active Antiretroviral Therapy (Canadian HIV Trials Network Study 164)

J. Singer, B. Conway, J. Macleod, 2007, Journal of acquired immune deficiency syndromes.

Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal

M. Wainberg, C. Tremblay, B. Brenner, 2004, AIDS.

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

Réjean Thomas, C. Costiniuk, M. Jenabian, 2015, HIV clinical trials.

Differential Impact of IL-32 Isoforms on the Functions of Coronary Artery Endothelial Cells: A Potential Link with Arterial Stiffness and Atherosclerosis

C. Tremblay, C. Chartrand-Lefebvre, J. Routy, 2023, Viruses.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

J. Montaner, B. Clotet, D. Kuritzkes, 2007, AIDS patient care and STDs.

Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak

M. Graham, D. Vinh, Réjean Thomas, 2022, Annals of Internal Medicine.

Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.

A. Rachlis, J. Angel, M. Harris, 2009, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial

J. Singer, J. Routy, M. Brouillette, 2014, Trials.

The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C.

B. Conway, P. Ghali, E. Yoshida, 2020, Canadian liver journal.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

D. Podzamczer, J. Mallolas, C. Orrell, 2017, HIV clinical trials.

Title Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA : A randomized , double-blind , placebo-controlled clinical trial Permalink

J. Routy, D. Margolis, D. Asmuth, 2022 .

Acute renal failure in four HIV-infected patients: Potential association with tenofovir and nonsteroidal anti-inflammatory drugs.

B. Trottier, A. Talbot, Suzanne Marcotte Bpharm, 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Association of epicardial fat with noncalcified coronary plaque volume and with low attenuation plaque in people with HIV

C. Tremblay, C. Chartrand-Lefebvre, Paule Bodson-Clermont, 2021, AIDS.

Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy–Treated Individuals With Undetectable Viremia

C. Chartrand-Lefebvre, M. Pazgier, W. Tolbert, 2023, The Journal of infectious diseases.